Lazard Asset Management LLC Sells 18,392 Shares of Tenet Healthcare Corporation $THC

Lazard Asset Management LLC lessened its stake in Tenet Healthcare Corporation (NYSE:THC) by 12.3% in the first quarter, HoldingsChannel reports. The firm owned 131,734 shares of the company’s stock after selling 18,392 shares during the period. Lazard Asset Management LLC’s holdings in Tenet Healthcare were worth $24,860,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Triumph Capital Management bought a new stake in shares of Tenet Healthcare in the third quarter worth $25,000. Activest Wealth Management bought a new position in Tenet Healthcare in the fourth quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in Tenet Healthcare in the fourth quarter worth about $29,000. Meeder Asset Management Inc. increased its position in shares of Tenet Healthcare by 146.2% during the 4th quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock valued at $38,000 after purchasing an additional 114 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of Tenet Healthcare in the 2nd quarter worth approximately $35,000. 95.44% of the stock is owned by institutional investors.

Tenet Healthcare News Roundup

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Strong Q2 results and improved outlook: Tenet beat analyst expectations for both earnings and revenue, while raising its 2026 forecast. Performance was driven by solid same-facility growth and disciplined expense management, reinforcing the company’s operating momentum. Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook
• Positive Sentiment: Analysts raise price targets: Truist increased its target to $290 from $270 and maintained a “buy” rating. Guggenheim raised its target to $283 from $242 and also rated the shares “buy.” The upgrades suggest analysts see further upside following the earnings beat and improved guidance. Analyst price-target updates
• Positive Sentiment: Growth-stock appeal: Zacks highlighted Tenet as a highly ranked growth stock, which could attract additional interest from growth, value and momentum-focused investors. Tenet Healthcare Is a Top-Ranked Growth Stock
• Neutral Sentiment: Mixed analyst signal: Robert W. Baird lifted its target sharply to $280 from $210 but retained a “neutral” rating, indicating improved valuation expectations without a full shift to a bullish stance. Analyst price-target update
• Negative Sentiment: Executive and director stock sales: EVP Paola M. Arbour sold 10,878 shares worth approximately $2.65 million, reducing her position by 37.14%. Director Christopher S. Lynch sold 3,837 shares worth about $934,000, cutting his ownership by 28.62%. Although these sales may be for personal or tax-related reasons, the sizable transactions could create a modest overhang for THC. Tenet Healthcare insider transaction filing

Insiders Place Their Bets

In other Tenet Healthcare news, Director Christopher S. Lynch sold 3,837 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $243.44, for a total transaction of $934,079.28. Following the completion of the sale, the director directly owned 9,568 shares of the company’s stock, valued at $2,329,233.92. This trade represents a 28.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nadja West sold 3,000 shares of Tenet Healthcare stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total transaction of $532,050.00. Following the sale, the director owned 24,805 shares in the company, valued at approximately $4,399,166.75. The trade was a 10.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 23,353 shares of company stock worth $5,103,217. Company insiders own 0.97% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Barclays boosted their target price on shares of Tenet Healthcare from $240.00 to $271.00 and gave the company an “overweight” rating in a research report on Friday. Robert W. Baird boosted their price objective on shares of Tenet Healthcare from $210.00 to $280.00 and gave the company a “neutral” rating in a research report on Tuesday. Truist Financial raised their target price on Tenet Healthcare from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Tuesday. Guggenheim boosted their price target on Tenet Healthcare from $242.00 to $283.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wells Fargo & Company raised their price objective on Tenet Healthcare from $213.00 to $231.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $268.50.

Tenet Healthcare Stock Up 7.8%

Shares of THC stock opened at $262.36 on Wednesday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.41 and a quick ratio of 1.35. Tenet Healthcare Corporation has a one year low of $155.02 and a one year high of $262.68. The company’s fifty day moving average price is $187.59 and its 200-day moving average price is $198.22. The company has a market capitalization of $22.60 billion, a price-to-earnings ratio of 10.12, a PEG ratio of 1.37 and a beta of 1.27.

Tenet Healthcare (NYSE:THC) last issued its earnings results on Friday, July 24th. The company reported $6.12 earnings per share for the quarter, topping the consensus estimate of $4.26 by $1.86. The company had revenue of $6.04 billion during the quarter, compared to the consensus estimate of $5.43 billion. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. Tenet Healthcare’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.02 EPS. Sell-side analysts expect that Tenet Healthcare Corporation will post 20.9 EPS for the current fiscal year.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.